Search Antibody Database

Found 1 matching record:

Displaying record number 478

Download this epitope record as JSON.

MAb ID	SP.SF2:104
HXB2 Location	gp160(308-317) DNA(7146..7175)	gp160 Epitope Map
Author Location	gp120( SF2)
Epitope	SIYIGPGRAF	Epitope Alignment
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing	L
Species (Isotype)	(IgG2aκ)
Patient
Immunogen	HIV-1 infection
Keywords

Notes

Showing 2 of 2 notes.

• SP.SF2:104: Authors suggest that during in vivo immunoselection of escape virus, the V3 domain gains increasing resemblance to lab strains. Arendrup1995
• SP.SF2:104: Anti-V3 antibody that could neutralize primary virus isolated from a time point of neutralization resistance of autologous virus. Arendrup1993

References

Showing 2 of 2 references.

Arendrup1993 M. Arendrup, A. Sonnerborg, B. Svennerholm, L. Akerblom, C. Nielsen, H. Clausen, S. Olofsson, J. O. Nielsen, and J. E. S. Hensen. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J. Gen. Virol., 74:855-863, 1993. PubMed ID: 7684062. Show all entries for this paper.

Arendrup1995 M. Arendrup, L. Akerblom, P. M. Heegaard, J. O. Nielsen, and J. E. Hansen. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arch. Virol., 140:655-670, 1995. The anti-V3 Ab titre in patient serum was generally low against autologous virus isolated later than the serum sample, in contrast to a higher titre against peptides corresponding to virus isolated earlier than the serum sample. The authors conclude that the V3 domain is subject to immunoselection in vivo, and that V3 on early field virus is less accessible to NAbs than the V3 loop on laboratory strains. PubMed ID: 7794110. Show all entries for this paper.